William Y. Ho
Fred Hutchinson Cancer Research Center
19 Papers
298 Citations
William Y. Ho is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Cytotoxic T cell & Antigen. The author has an hindex of 9, co-authored 16 publications. Previous affiliations of William Y. Ho include University of Washington.
Chat about Author
Papers
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
Marc A. Gavin,Troy R. Torgerson,Evan G. Houston,Paul deRoos,William Y. Ho,Asbjørg Stray-Pedersen,Elizabeth L. Ocheltree,Philip D. Greenberg,Hans D. Ochs,Alexander Y. Rudensky +9 more
TL;DR: Forkhead winged-helix transcription factor Foxp3 serves as the dedicated mediator of the genetic program governing CD25+CD4+ regulatory T cell (T(R)) development and function in mice and the relationship between FOXP3 expression and human T(R) development is addressed.
832
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis,Gunnar B. Ragnarsson,Hieu Nguyen,Colette Chaney,Jeffrey S. Pufnock,Thomas M. Schmitt,Natalie Duerkopp,Ilana M. Roberts,Galina Pogosov,William Y. Ho,Sebastian Ochsenreither,Matthias Wolfl,Merav Bar,Jerald P. Radich,Cassian Yee,Philip D. Greenberg,Philip D. Greenberg +16 more
TL;DR: A way to harness the power of the donors’ immune cells against some leukemias, without triggering GVHD in the bone marrow recipients is reported, supporting the idea that WT1 targeting is specific to the tumor cells and safe for patient use.
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.
TL;DR: Adoptive T cell immunotherapy is an evolving technology with the potential of providing a means to safely and effectively target tumor cells for destruction.
190
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
TL;DR: Using these techniques, high-avidity CTL clones specific for an A()0201-restricted epitope of WT1 have been generated from nearly all normal A2(+) donors tested, and will soon be tested for therapeutic activity in clinical trials of adoptive immunotherapy in patients with relapsed leukemia after transplantation.
147
Adoptive therapy with CD8+ T cells: it may get by with a little help from its friends
TL;DR: A murine model of immunity against the intracellular bacterium Listeria monocytogenes is used to evaluate a potential obstacle to T cell therapy, and the utility of providing an inflammatory stimulus (CD40 activation) to rescue otherwise ineffective adoptively transferred CD8 + T cells is demonstrated.